Results 81 to 90 of about 22,017 (188)

KINETIC MODELING APPROACH TO IN VIVO INTERACTIONS OF CURCUMIN AND CURCUMINOID-PIPERINE MIXTURE WITH QUETIAPINE

Studia Universitatis Babes-Bolyai Chemia
This study aimed to develop kinetic models that describe the preclinical drug interaction data between quetiapine, an atypical antipsychotic, and bioactive compounds derived from turmeric rhizome.
Iulia Maria CIOCOTIȘAN, Dana Maria MUNTEAN, Laurian VLASE   +2 more
doaj   +1 more source

Brexpiprazole and Quetiapine Use During Pregnancy and Lactation: A Case Report

Clinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT Brexpiprazole, used off‐label in combination with quetiapine, may be a treatment option during pregnancy and breastfeeding when the risk of maternal relapse outweighs potential fetal or infant risks. This case describes perinatal use of polypharmacy without apparent adverse maternal or infant outcomes, underscoring the need for individualized,
Awateif Alsupiany
wiley   +1 more source

A Novel Workflow for Fast Elucidation of Drug Metabolites for Screening—Combining In Silico Metabolite Prediction With Trapped Ion Mobility QTOF‐MS

Drug Testing and Analysis, Volume 18, Issue 7, Page 841-851, July 2026.
UHPLC‐timsTOF‐MS with in silico prediction and automated annotation enabled rapid identification of quetiapine metabolites from pHLMs, facilitating their inclusion in targeted LC‐QTOF‐MS urine screening and improving biomarker detection for toxicological applications.
Annette Zschiesche, Birgit Schneider, Ilona Nordhorn, Carsten Baessmann, Laura M. Huppertz, Jürgen Kempf   +5 more
wiley   +1 more source

Effectiveness of a Psychiatrist‐Led Clinic for Metabolic Health in Severe Mental Illness: A Retrospective Chart Review Study

Acta Psychiatrica Scandinavica, Volume 154, Issue 1, Page 74-88, July 2026.
ABSTRACT Background Psychotropic medications are associated with serious metabolic adverse effects, which contribute to an increased risk of cardiometabolic comorbidities in patients with severe mental illness (SMI). Several intervention strategies are available to mitigate these metabolic adverse effects; however, data on their utility in real‐world ...
Nicolette Stogios, Femin Prasad, Riddhita De, Kateryna Maksyutynska, Akash PrasannaKumar, Vittal Korann, Tariq Ahmed, Marcos Sanches, Leah Burton, Mohammed A. Alarabi, Tanner Isinger, Michelle Desanti, Rebecca Oliveira, Daphne J. Korczak, Ariel Graff‐Guerrero, Gary Remington, Margaret K. Hahn, Sri Mahavir Agarwal   +17 more
wiley   +1 more source

Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials

Drug Design, Development and Therapy, 2016
Narong Maneeton,1 Benchalak Maneeton,1 Pakapan Woottiluk,2 Surinporn Likhitsathian,1 Sirijit Suttajit,1 Vudhichai Boonyanaruthee,1 Manit Srisurapanont1 1Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand ...
Maneeton N, Maneeton B, Woottiluk P, Likhitsathian S, Suttajit S, Boonyanaruthee V, Srisurapanont M   +6 more
doaj  

Health, Social and Recidivism Outcomes Among People Who Have Been Incarcerated in New South Wales, Australia: Study Protocol and Cohort Profile for the Prison Outcomes STudy (POST)

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction We have been funded to examine post‐incarceration health and social outcomes for all people incarcerated in New South Wales, Australia, 2000–2022; assess treatment and services for drug dependence and serious mental illness; and project the impact of expanding intervention coverage. We will use a linked cohort, the Prison Outcomes
Louisa Degenhardt, Michael Farrell, Michael Doyle, Jack Stone, Chrianna Bharat, Matt Hickman, Marianne Martinello, Don Weatherburn, Kimberlie Dean, Joe Coyte, Christel Macdonald, Mary Ellen Harrod, Luke Grant, Gloria Larman, Peter Vickerman, Colette McGrath, Peter Thompson, Alison Churchill, Greg Dore, Thomas Santo Jr   +19 more
wiley   +1 more source

Accuracy of Patient‐Reported Exposure to New Psychoactive Substances and Other Illicit Drugs in Australian Emergency Departments: Findings From the Emerging Drugs Network of Australia

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction New psychoactive substances (NPS) present a unique challenge in clinical, public health and drug‐policy contexts. Continued diversity, unknown potency and often unintentional exposure can limit the accuracy of self‐reported data.
Marjan J. Nijmeijer, Jennifer L. Smith, Courtney Weber, Bas W. J. Bens, Daniel M. Fatovich, Shaun L. Greene, Jennifer L. Schumann, Paul Dessauer, Rebekka Syrjanen, Katherine Z. Isoardi, Keith Harris, Sam Alfred, Viet Tran, Ewoud ter Avest   +13 more
wiley   +1 more source

Hemodialysis Treatment for High-Dose Quetiapine Fumarate Poisoning: A Case Report

Case Reports in Nephrology and Dialysis
Introduction: Quetiapine is a new atypical antipsychotic with minor side effects. There have been few reports of rhabdomyolysis and acute kidney injury associated with quetiapine overdose.
Jiaoyang Li, Zhiqin Chen, Shuran Qian, Xuemei Liu   +3 more
doaj   +1 more source

Effectiveness of Alcohol Use Disorder Pharmacotherapies by Sex: Systematic Review and Meta‐Analysis

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Issues Alcohol use disorder (AUD) shows sex‐related differences in prevalence, harm and treatment response. Despite growing interest in sex differences, evidence synthesis evaluating pharmacotherapy effectiveness by sex remains limited. Approach Web of Science, PubMed, Scopus, PsycINFO and Cochrane were searched twice.
Juliette Allen, Andrew Jones, Gillian W. Shorter, Catharine Montgomery, Zetta Kougiali, Alina Bagnall, Claire Adshead, Jessie Smith, Sam Burton, Amanda Atkinson, Lillian Guelen, Abigail Rose   +11 more
wiley   +1 more source

Narrative Review of Catatonia in Psychosis and Eating Disorders: Common Intersections and Treatment Considerations

Early Intervention in Psychiatry, Volume 20, Issue 7, July 2026.
ABSTRACT Background Eating disorders (ED) and psychosis/psychotic‐spectrum disorders (PSD) have overlapping symptoms and may co‐occur in a variety of presentations. Due to its debilitating and life‐threatening risk, it is important for clinicians to be aware of how catatonia may present within these co‐occurrences.
Rosiel Elwyn
wiley   +1 more source